New indication: treatment of small cell lung cancer after failure of first-line chemotherapy. Previously approved as second-line therapy to treat advanced ovarian cancer. Note: Clinical trials continue regarding the use of Hycamtin in combination with ara-C (cytosine arabinoside) in the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). It is also being investigated as a possible treatment for acute and chronic leukemia; pediatric cancer; breast, colorectal, and lung cancers. Mfg: SmithKline Beecham. Source: PR Newswire - 12/09/97; 12/03/98.